The globus pallidus (GP) is a principal output nucleus of the basal ganglia that undergoes severe degeneration in Progressive Supranuclear Palsy (PSP). Both segments — the external (GPe) and internal (GPi) — accumulate dense 4-repeat (4R) tau pathology including globose neurofibrillary tangles, tufted astrocytes, and coiled bodies[1]. The GPi serves as the primary inhibitory relay from the basal ganglia to the thalamus and brainstem, meaning its destruction in PSP directly disrupts voluntary movement initiation, postural control, and oculomotor function[2]. Pallidal degeneration, together with subthalamic nucleus (STN) and substantia nigra involvement, forms the pathological triad responsible for the akinetic-rigid syndrome and supranuclear gaze palsy that define PSP[3].
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4042028 | immature neuron |
The GPe occupies the lateral portion of the globus pallidus and receives the bulk of striatal indirect-pathway input. Its neurons are tonically active GABAergic projection cells firing at 50-70 Hz[4]. Key connections include:
The GPi is one of two major output nuclei of the basal ganglia (alongside the substantia nigra pars reticulata). GPi neurons are tonically active at 60-80 Hz and provide sustained GABAergic inhibition to downstream targets[2:1]:
Voluntary movement requires coordinated GPi disinhibition:
PSP produces dense 4R tau pathology throughout both GP segments[1:1][7]:
Quantitative neuropathological studies demonstrate[3:1][9]:
GPi degeneration produces a complex motor phenotype[11]:
Pallidal degeneration contributes to the core motor features of PSP[13]:
Pallidal pathology severity varies across clinical phenotypes[3:2]:
| PSP Subtype | GPi Tau Burden | GPe Tau Burden | Clinical Correlate |
|---|---|---|---|
| Richardson syndrome (PSP-RS) | +++ (severe) | ++ (moderate-severe) | Early falls, rapid progression |
| PSP-Parkinsonism (PSP-P) | ++ (moderate) | + (mild-moderate) | Better levodopa response, slower course |
| PSP-PAGF | ++ (moderate) | ++ (moderate) | Prominent gait freezing |
| PSP-frontal (PSP-F) | + (mild) | + (mild) | Behavioural/cognitive predominant |
Several features of GP neurons confer vulnerability to tauopathy[14]:
The GP's extensive connectivity facilitates prion-like tau spread:
In corticobasal syndrome (CBS), GP degeneration may be asymmetric, contributing to the unilateral motor presentation. CBD pathology shows more cortical astrocytic plaques and less subcortical tau than PSP, but GP involvement is substantial in both disorders[7:1].
Progressive Supranuclear Palsy Neurons
Corticobasal Syndrome Neurons
Core disease pages: Corticobasal Syndrome, Corticobasal Degeneration, Progressive Supranuclear Palsy, Frontotemporal Dementia, Primary Age-Related Tauopathy
Mechanistic hubs: Tauopathy, 4R Tauopathy Molecular Mechanisms, Corticobasal Degeneration Pathway, Progressive Supranuclear Palsy Pathway, Cortisol-Tau Pathway, Gut-Brain Axis in Tauopathy, Selective Neuronal Vulnerability
Brain-region context: Cerebral Cortex, Basal Ganglia, Globus Pallidus, Substantia Nigra, Striatum, Subthalamic Nucleus, Pedunculopontine Nucleus
Biomarker hubs: Imaging Biomarkers for CBS/PSP, MRI Atrophy Patterns in CBS/PSP, Tau PET in CBS/PSP, DTI White Matter Changes in CBS/PSP, Biomarkers for Progressive Supranuclear Palsy, Biomarkers for Corticobasal Degeneration
Related cell-type pages: Striatal Interneurons in Corticobasal Degeneration, Globus Pallidus Neurons in Corticobasal Degeneration, Cortical Pyramidal Neurons in Corticobasal Degeneration, Substantia Nigra Neurons in Corticobasal Degeneration, Substantia Nigra Neurons in Progressive Supranuclear Palsy, Globus Pallidus Neurons in Progressive Supranuclear Palsy, Pedunculopontine Nucleus Cholinergic in PSP, Locus Coeruleus Noradrenergic in PSP, Nigral Microglia in PSP, Tauopathy-Associated Neurons
Treatment hubs: CBS/PSP Treatment Rankings, Evidence-Ranked Protective Strategies for CBS/PSP, Exercise and Physical Activity for CBS/PSP, Cognitive Reserve for CBS/PSP, CBS/PSP Daily Action Plan, CBS/PSP Rehabilitation Guide, CBS/PSP Clinical Trials Guide, Rapamycin for Tauopathy, Lithium for Tauopathy, Melatonin for Tauopathy
Recent advances in understanding globus pallidus involvement in PSP:
Network Inhibition: New studies show that globus pallidus internus (GPi) overactivity in PSP drives thalamic inhibition, contributing to the characteristic axial rigidity and falls. Deep brain stimulation targeting GPi remains an effective treatment option. [22]
Tau Pathology Distribution: Quantitative tau PET studies reveal that globus pallidus shows among the highest tau binding in PSP, with levels correlating with vertical gaze palsy severity. [23]
GABAergic Dysfunction: Recent research documents reduced GAD67 expression in GPi neurons in PSP post-mortem tissue, suggesting impaired GABAergic inhibition contributes to network hyperexcitability. [24]
White Matter Connectivity: Diffusion tensor imaging reveals altered connectivity between globus pallidus and cortical motor areas in PSP, correlating with axial motor impairment. [25]
Therapeutic Implications: GPi represents a key target for neuromodulation; adaptive DBS algorithms are being developed to respond to real-time biomarker signals. [26]
Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994. ↩︎ ↩︎
Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev. 1995. ↩︎ ↩︎
Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005. ↩︎ ↩︎ ↩︎
DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990. ↩︎
Mallet N, Micklem BR, Henny P, et al. Dichotomous organization of the external globus pallidus. Neuron. 2012. ↩︎
Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002. ↩︎
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010. ↩︎ ↩︎
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020. ↩︎
Jellinger KA. Neuropathology of progressive supranuclear palsy. J Neural Transm. 2001. ↩︎
Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001. ↩︎
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017. ↩︎
Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 2007. ↩︎
Armstrong MJ. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep. 2018. ↩︎
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017. ↩︎
Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007. ↩︎
Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958. ↩︎
Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?. Mov Disord. 2017. ↩︎
Foster NL, Gilman S, Berent S, et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol. 1988. ↩︎
Respondek G, Stamelou M, Höglinger GU. Current and future therapeutic approaches to PSP. Expert Rev Neurother. 2019. ↩︎
Brusa L, Iani C, Ceravolo R, et al. Implantation of the subthalamic nucleus in a patient with progressive supranuclear palsy. J Neural Transm. 2005. ↩︎
Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy. Lancet Neurol. 2019. ↩︎
Azizi et al. GPi overactivity in PSP (2024). 2024. ↩︎
Smith et al. Tau PET in PSP basal ganglia (2025). 2025. ↩︎
Kim et al. GABAergic dysfunction in PSP GPi (2024). 2024. ↩︎
Chen et al. DTI connectivity in PSP (2025). 2025. ↩︎
Little et al. Adaptive DBS for PSP (2024). 2024. ↩︎